Insider Selling: Exelixis (NASDAQ:EXEL) EVP Sells 34,187 Shares of Stock

Exelixis, Inc. (NASDAQ:EXEL) EVP Patrick Haley sold 34,187 shares of the stock in a transaction that occurred on Thursday, November 20th. The shares were sold at an average price of $41.88, for a total value of $1,431,751.56. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Exelixis Trading Down 0.6%

EXEL traded down $0.26 on Monday, hitting $42.25. 3,975,801 shares of the company were exchanged, compared to its average volume of 2,953,427. The firm has a 50-day moving average price of $39.93 and a two-hundred day moving average price of $40.73. The company has a market cap of $11.33 billion, a price-to-earnings ratio of 20.31, a price-to-earnings-growth ratio of 0.79 and a beta of 0.32. Exelixis, Inc. has a twelve month low of $31.90 and a twelve month high of $49.62.

Exelixis (NASDAQ:EXEL) last posted its quarterly earnings data on Tuesday, November 4th. The biotechnology company reported $0.78 EPS for the quarter, beating the consensus estimate of $0.68 by $0.10. The firm had revenue of $597.76 million during the quarter, compared to the consensus estimate of $590.04 million. Exelixis had a return on equity of 27.47% and a net margin of 27.01%.The firm’s revenue was up 10.8% compared to the same quarter last year. During the same period in the prior year, the business earned $0.47 EPS. Exelixis has set its FY 2025 guidance at EPS. Equities analysts expect that Exelixis, Inc. will post 2.04 EPS for the current year.

Institutional Investors Weigh In On Exelixis

Hedge funds and other institutional investors have recently modified their holdings of the stock. Richardson Financial Services Inc. boosted its position in shares of Exelixis by 95.1% during the third quarter. Richardson Financial Services Inc. now owns 599 shares of the biotechnology company’s stock valued at $25,000 after purchasing an additional 292 shares in the last quarter. Anchor Investment Management LLC lifted its holdings in Exelixis by 500.0% in the 3rd quarter. Anchor Investment Management LLC now owns 600 shares of the biotechnology company’s stock worth $25,000 after purchasing an additional 500 shares in the last quarter. Hemington Wealth Management boosted its position in shares of Exelixis by 211.3% during the 1st quarter. Hemington Wealth Management now owns 769 shares of the biotechnology company’s stock valued at $28,000 after acquiring an additional 522 shares during the last quarter. Root Financial Partners LLC purchased a new stake in Exelixis during the 3rd quarter valued at $28,000. Finally, Byrne Asset Management LLC grew its position in Exelixis by 129.0% in the 2nd quarter. Byrne Asset Management LLC now owns 710 shares of the biotechnology company’s stock valued at $31,000 after acquiring an additional 400 shares during the last quarter. Institutional investors own 85.27% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on the company. Cowen reaffirmed a “buy” rating on shares of Exelixis in a research report on Wednesday, November 5th. The Goldman Sachs Group began coverage on Exelixis in a research note on Wednesday, September 17th. They set a “buy” rating and a $47.00 price target on the stock. Wells Fargo & Company dropped their target price on shares of Exelixis from $36.00 to $30.00 and set an “equal weight” rating for the company in a research note on Tuesday, October 21st. JMP Securities reiterated a “market outperform” rating and set a $50.00 price objective on shares of Exelixis in a report on Tuesday, July 29th. Finally, Weiss Ratings restated a “buy (b)” rating on shares of Exelixis in a report on Wednesday, October 8th. One research analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and twelve have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $45.45.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.